DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.

How Biotech is Forcing Big Pharma's Hand

by Nathan Brinkman

Big Pharma is under the gun. With an estimated $236 billion in annual revenues at risk from patent cliffs by 2030 and over $1.4 trillion in combined deal firepower burning a hole in balance sheets, the urgency to acquire late-stage biotech assets has never been greater. Yet a new dynamic is reshaping the negotiating table: the targets are the ones setting the terms and the message to would-be acquirers is pointed. If you wait much longer, our price goes up.

This is not passive optimism. It is a calculated, data-driven negotiating posture. When Merck reportedly offered $28–32 billion for Revolution Medicines and was turned away, and when Eli Lilly’s rumored €15 billion approach to Abivax never became a formal bid, it was because both targets knew something their suitors did not want to acknowledge: imminent Phase 3 readouts will render any current offer obsolete. Boards with sufficient cash to survive, and science credible enough to command attention, are choosing to run the clock. The companies below are doing exactly that.

Abivax (ABVX), Kyverna Therapeutics (KVTX), and Revolution Medicines (RVMD) are pre-revenue biotech companies, each with expected near-term market catalysts that will likely impact their long term value. Each offers a high risk, high reward through these upcoming catalysts or through a high priced acquisition potential which could take place prior to release of their market catalyst.